focus -WSS

focus

author：explore 2025-08-12 09:13:29 - browse：2

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Readout Newsletter: XBI biotech index, Akero Therapeutics

WSS

Emergency medicine has repudiated 'excited delirium.' Now what?

The FDA weighs the risks of candy

Readout Newsletter: XBI biotech index, Akero Therapeutics

Readout Newsletter: XBI biotech index, Akero Therapeutics

Vermont grapples with historic flooding as more rainstorms head for Northeast

Meta's Zuckerberg and Chan on track to put $50 billion into science

hotspot

focus

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The FDA weighs the risks of candy

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

DIEP, the 'gold standard' of breast reconstruction, is under threat

Grail's uphill battle for Medicare to cover its cancer screening test

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Inflation cooled significantly in June, bringing price hikes close to normal levels

Alkermes shareholders re

Maker of FluMist seeks to allow at

explore

Telehealth options flood the market as retailers push virtual care

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

FDA has safety concerns on CRISPR

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

Readout Newsletter: New research from Sanofi, Regeneron, etc.

hotspot

hotspot

focus

hotspot